Omeros Slumps: OMER Falls 10.4% in Session

Zacks Equity Research
July 9, 2014

Omeros Corporation (OMER) saw a big move last session, as the company’s shares fell by over 10% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for OMER as the stock is now up over 5% since Jun 19.

The biopharmaceutical company has seen a flat track record when it comes to current year estimate revisions over the past 30 days, and the consensus for earnings hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future, and especially on earnings estimates following the recent slump.

OMER currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the Medical Products sector include Agios Pharmaceuticals, Inc. (AGIO), Cardiovascular Systems Inc. (CSII) and Hospira Inc. (HSP). All these stocks hold a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>




(OMERAGIOCSIIHSP): Free Stock Analysis Report


Zacks Investment Research